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Abstract
Background: The prognosis of patients with Ewing sarcoma (ES) has improved over the course of the last decades.
However, those patients suffering from metastatic and recurrent ES still have only poor chances of survival and
require new therapeutic approaches. Interleukin-6 (IL6) is a pleiotropic cytokine expressed by immune cells and a
great variety of cancer cells. It induces inflammatory responses, enhances proliferation and inhibits apoptosis in
cancer cells, thereby promoting chemoresistance.
Methods: We investigated expression of IL6, its receptors and the IL6 signal transduction pathway in ES tumor
samples and cell lines applying reverse transcriptase PCR, immunoblot and immunohistochemistry. The impact of
IL6 on cell viability and apoptosis in ES cell lines was analyzed by MTT and propidium iodide staining, migration
assessed by chorioallantoic membrane (CAM) assay.
Results: Immunohistochemistry proved IL6 expression in the stroma of ES tumor samples. IL6 receptor subunits IL6R
and IL6ST were expressed on the surface of ES cells. Treatment of ES cells with rhIL6 resulted in phosphorylation of
STAT3. rhIL6 protected ES cells from serum starvation-induced apoptosis and promoted migration. IL6 blood serum
levels were elevated in a subgroup of ES patients with poor prognosis.
Conclusions: These data suggest that IL6 contributes to ES tumor progression by increasing resistance to apoptosis in
conditions of cellular stress, such as serum starvation, and by promotion of metastasis.
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Background
Over the course of the last 20 years survival rates for
patients with Ewing sarcoma have increased as a con-
sequence of therapy intensification, improvement of
surgical techniques and radiotherapy. However, even
with multimodal therapy regimens including intensive
chemotherapy and interval compression 5-year EFS
for patients with ES is around 70 % [1, 2]. In recent
years, a multitude of new insights into the biology of
ES cells has been made allowing the introduction and
development of targeted ES therapies [3]. In particu-
lar, patients suffering from metastatic and recurrent
disease with long term overall survival rates of only
around 20% are in need of such new therapeutic ap-
proaches [4].
Genetic alterations serve as the basis for disturbed
signaling pathways. Analysis of gene expression data
from ES cell lines after inhibition of EWS-FLI1 expres-
sion demonstrated that several mediators of inflamma-
tion, including SOCS3, IL6ST, IL-1-accessory protein
and IL-8 are regulated by EWS-FLI1 [5]. Inflammation
plays an important role in the development of a great
variety of tumors (reviewed in [6, 7]). In terms of the
clinical presentation of ES, it is well known that the
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distinction between osteomyelitis and malignancy can
often be made via biopsy only [8]. In line with this, pa-
tients suffering from ES often present with fever, itself
indicating a worse prognosis [9]. Moreover, elevated
IL6 levels in peripheral blood of patients with bone sar-
comas correlate with higher tumor extension and de-
creased overall survival [10].
In other malignant diseases, such as Hodgkin’s lymph-
oma or neuroblastoma, high IL6 blood serum expression
is associated with poor prognosis [11, 12]. In multiple
myeloma cells IL6 inhibits apoptosis from dexametha-
sone, serum starvation and FAS-ligand [13]. In neuro-
blastoma IL6 protects cells from drug-induced apoptosis
and increases proliferation [14]. Tumor cells derived
from epithelial tissues like mammary, prostate and colon
carcinoma show increased IL6-induced expression of
BCL-XL [15, 16], Hsp70 [16], cyclin A1 [17], and Mcl1
[18]. In addition to inhibiting apoptosis, IL6 signaling is
also known to promote migration and invasion in a great
variety of tumors including ovarian cancer, breast cancer,
glioblastoma and chondrosarcoma [19–22].
The biological effects of IL6 are mediated via the IL6
receptor complex consisting of IL6ST, the signal trans-
ducing component expressed in a great variety of human
tissues, and the specific IL6 binding subunit IL6R, which
is found membrane-bound on the cell surface and sol-
uble in the sera of patients. The soluble IL6R subunit
mediates IL6-trans-signaling through formation of an
IL6/IL6R complex, which interacts with membrane
bound IL6ST. This permits IL6 signaling even in those
cells which do not express IL6R [23, 24]. Examination of
the complex interactions of IL6, IL6R and IL6ST by
Boulanger et al. revealed that interaction of IL6 and
IL6R is followed by tertiary and quaternary changes of
protein structure alleviating binding to IL6ST. The result
is transition to a hexamer which is highly competent to
transduce the extracellular signal [25]. The main signal-
ing pathways activated by IL6 are the STAT3- and
MAPK-pathways leading to altered gene expression,
which among others comprise genes related to metasta-
sis, apoptosis and proliferation [26].
Since inflammation plays a significant role in the clin-
ical presentation of ES and elevated IL6 levels - associ-
ated with poor prognosis - are found in ES patients, we
have analyzed the expression and functionality of the
IL6/IL6R system in ES.
Methods
Patients and tissue samples
All but one tumor specimen and all serum samples used
in this study were obtained at the time of initial diagno-
sis; for one patient, in addition, a tumor sample at the
diagnosis of relapse was included. Clinical information
on patients whose samples were used in this study is
summarized in Additional file 3: Table S1. All patients
were diagnosed with Ewing sarcoma during the years of
1990 through 2012 and treated according to the proto-
cols CESS 86, EICESS 92, EURO-Ewing 99 or Ewing
2008. Diagnosis of Ewing sarcoma was made based on
histological appearance, cytogenetics and RT-PCR for
EWS-ETS fusion; all tumors were reviewed by a refer-
ence pathologist within the EURO-Ewing study. No
extraosseus tumors were included. All patients were
treated at the University Hospital Freiburg. The investi-
gations performed are in compliance with the Helsinki
Declaration. Informed consent was obtained from all pa-
tients or their legal guardians and the analysis was ap-
proved by the ethics committee of the University of
Freiburg.
Due to limited availability of material, samples used
for PCR studies were mostly from different patients than
serum and immunohistochemistry samples. Biopsies
used for PCR were shock frozen and stored at −196 °C in
liquid nitrogen. Serum was stored at −80 °C prior to meas-
urement of IL6 using the ELISA-Kit IMMULITE 2000
IL6, Siemens Medical Solutions Diagnostics, Eschborn,
Germany.
Immunohistochemistry
For immunohistochemical staining, 3 μm sections of for-
malin fixed, paraffin embedded tissue samples were
deparaffinzed by xylene and rehydrated by decreasing
concentrations of ethanol. After heat induced antigen re-
trieval by pH9 Tris buffer (DAKO, Carpinteria, CA,
USA), endogenous peroxidase activity was deactivated
by 3 % hydrogen peroxide. Nonspecific protein binding
sites were blocked by Protein Block (DAKO, Carpinteria,
CA, USA). αIL6 polyclonal rabbit antibody (Cat-No:
ab662 Abcam, Cambridge, UK) was incubated with the
slides for 60 min. For detection, the polymer-based Envi-
sion Kit by DAKO (Carpinteria, CA, USA) was applied,
including a secondary antibody and DAB (diaminoben-
zidine) for staining. After counterstain by hematoxylin,
dehydration and coverslipping, stained sections were
evaluated and digitized for histological photographs
and quantification of staining (Hamamatsu NanoZoo-
mer 2.0 HT, Hamamatsu Photonics, Hersching am
Ammersee, Germany). Scoring of immunohistochemi-
cal staining for IL6, vimentin and smooth muscle anti-
gen (SMA) was done as follows. Samples were scored
as positive (+) in cases of intermedium/strong staining
in more than 50 % of tissue or cell content. In addition,
staining for IL6 was quantitatively analyzed by the area
of stained cells/extracellular space and semi quantita-
tively by the intensity of staining. Distribution of stain-
ing was evaluated on the entire tumor section using a
20× lens. The percentage of positive cells/extracellular
space within various fields was determined, and a mean
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score was calculated. The intensity was scored as no
signal (0), weak signal (1), or intermedium (2) to strong
signal (3). (Additional file 4: Table S2).
Cell lines and culture
Seven cell lines were used in this study. The ES cell lines
A4573, TC71, TC32, SK-N-MC, CHP-100 and JR were
kindly provided by Jeff Toretsky (Georgetown University,
Washington D.C., USA). Biological characteristics of
these lines have been described earlier [27]. The cell line
NK, positive for the EWS/FLI1 fusion, has been newly
derived in our laboratory from the tumor of a patient
with metastatic ES. The IL6 negative prostate cancer cell
line LNCaP was a gift from Eric Metzler (Department of
Experimental Urology, University Hospital, Freiburg).
Conditions of cell culture included RPMI media supple-
mented with 10 % fetal calf serum (FCS), 100,000 IU/ml
Penicilline, 100 μg/ml Streptomycine, temperature of 37 °C
and 5 % CO2 atmosphere in the incubator. Condition of
serum starvation as experimental setting was induced by
medium change to medium without supplements 24 h
after seeding.
Reagents
Recombinant human IL6 (rhIL6, Cat. No 206-IL) and hu-
man anti-IL6R antibody (clone 17506, Cat. No MAB227)
were purchased from R&D Systems, Minneapolis, USA.
Antibodies used for immunoblot included rabbit anti-
phospho-STAT3 polyclonal antibody (Cat. No 9131) and
rabbit anti-STAT3 polyclonal antibody(Cat. No 9132), Cell
Signaling TECHNOLOGY®, Frankfurt, Germany, anti-
β-actin monoclonal antibody, clone AC-15, Sigma Al-
drich, Munich, Germany, goat anti-mouse IgG-HRP
and goat anti-rabbit IgG-HRP, Santa Cruz Biotechnol-
ogy, Heidelberg, Germany. The mouse anti-γ1 PE,
clone X40, BD Biosciences, Erembodegem, Belgium,
mouse anti-human IL6R-phycoerythrin, clone 17506,
R&D Systems, Minneapolis, USA and mouse anti-
human CD130 PE, clone AM64, BD Pharmingen, San
Diego, USA were used for flow cytometric analyses.
RT-PCR
The following primers, synthesized by Eurofins MWG
Synthesis GmbH, Ebersberg, Germany, were used in
PCR reactions as published previously: IL6 [28], IL6ST
[29], IL6R [30] and GAPDH [31]. Primer sequences are
summarized in Additional file 5: Table S3. For RT-PCR,
RNA extraction was performed using TRIzol, Invitrogen,
Carlsbad, USA, and cDNA synthesis was done using the
quantiscript protocol, Qiagen, Hilden, Germany. Primer
annealing temperatures and cycling parameters were
established individually for each gene of interest.
Immunoblot
Immunoblot was performed as described before [32].
The first antibody (dilution 1:1,000 in PBS and 5 % bovine
serum albumin) was incubated at 4 °C for 12 h. After
washing the membrane three times, a secondary antibody
was added for 30 min at room temperature, dilution
1:10,000 in PBS and 5 % BSA. Washing was repeated three
times. Then, the protein of interest was made visible by
chemoluminescence using ECL, Amersham/GE Health-
care Europe, Freiburg, Germany.
Flow cytometric analysis of cell surface receptor
expression
Staining of cell surface receptors was performed as de-
scribed before [33]. In brief, cells were mechanically re-
moved by gentle pipetting, washed twice and resuspended
in cold (4 °C) PBS followed by an incubation with anti-
human IL6R-phycoerythrin, anti-human CD130 PE and
mouse anti-γ1 PE (30 min, 4 °C, dark room). A minimum
of 10,000 cells was analyzed for IL6R and IL6ST cell sur-




Cells were seeded in 96-well plates in medium with sup-
plements as stated above, 5,000 cells/well, 100 μl/well
and incubated overnight. 24 h afterward, medium was
changed to medium without supplements. IL6 (10 ng/ml,
50 ng/ml and 100 ng/ml) was added on days 0 or 0, 2 and
4, respectively. The number of viable cells was inferred on
days 3, 4 and 5 from the tetrazolium-reducing activity of
mitochondrial dehydrogenases using the MTT-assay as
described before [32]. Absorbance was measured at 570
and 620 nm using the spectra sunrise absorbance reader,
Tecan, Männedorf, Switzerland. Background subtracted
absorbance (i.e. 570 nm - 620 nm) was plotted as function
of treatment.
Apoptosis stain with propidium iodide
Cells were plated and treated as specified in the MTT
section. On day 5, cells were harvested, centrifuged
(1,000 rpm, 4 °C, 5 min) and washed with cold PBS.
After another centrifugation step (1,000 rpm, 4 °C,
5 min) cells were incubated at 4 °C in hypotonic pro-
pidium iodide buffer as described before [32]. DNA
length with a focus on the sub G1 section was mea-
sured using FACScan (Becton Dickinson, Heidelberg,
Germany). 10,000 cells were measured per sample.
CAM-Assay
2.5 × 106 cells of ES cell line A4573, engineered to stably
overexpress green fluorescent protein (i.e. A4573/GFP),
where initially inoculated on the chorioallantoic membrane
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(CAM) of ex ovo prepared live chick embryos on day 9
(d9) of development (see reference [34] for details of egg
preparation and CAM assay). On d10 three explants, each
growing on a separate embryo, received in their immediate
vicinity a bolus of 10 μl of a) PBS (control), b) 25 ng/μl IL6
(250 ng IL6) and c) 50 ng/μl IL6 (500 ng IL6), which was
dissolved in PBS. On d14 A4573/GFP cells were quanti-
tated under a fluorescent microscope as function of migra-
tion distance from the perimeter of the explant. For that
purpose three images per tumor were taken, each superim-
posed by a 15 × 12 square grid that allowed to subdivide
the entire image into five equal-size zones (each with 3 ×
12 square area): zones 5 + 4 (= tumor core), 3 (tumor
edge), 2 (near migration) and 1 (far migration). Cell cover-
age in each square was estimated for zones 3, 2 and 1 with
values ranging from 0 (no cells present) to 5 (square 100 %
filled with cells). Mean (± SEM) zone 1–3 coverage values
of n = 3 independent experiments were computed for all
three images per tumor as a measure of cell motility in re-
sponse to PBS, 250 ng and 500 ng IL6.
IL6 Elisa
For detection of IL6 in the supernatant cells were plated
in 24-well plates at a concentration of 100,000 cells/well
in 500 μl medium without supplements and incubated for
48 h. After centrifugation of the supernatant (1,000 rpm,
4 °C, 5 min) IL6 was measured using the ELISA-Kit
IMMULITE 2000 IL6, Siemens Medical Solutions Diag-
nostics, Eschborn, Germany. The lowest detection level
was 2 pg/ml.
Statistics
Statistical analysis was performed using SPSS for Win-
dows 20 (IBM Corp., Armonk, New York, USA). For stat-
istical analysis of MTT and flow cytometry box plots were
used to describe the distribution of the data. Since normal
distribution could not be shown, median values and
ranges were reported and nonparametric statistics were
used to test differences among variables (Kruskal-Wallis
rank test with adjacent post-hoc Mann–Whitney-U-Test).
For CAM assay statistical differences among mean cover-
ages of IL6-treated vs. control (PBS) treated explants were
tested with non-parametric Wilcoxon rank sum tests.
All p-values were 2-sided and values equal or less than
0.05 were considered statistically significant. P values
greater than 0.1 were reported as non-significant.
Results
A subgroup of ES patients shows elevated IL6 serum
levels at diagnosis
IL6 serum levels were analyzed by ELISA in 12 ES pa-
tients at the time of diagnosis. IL6 levels above the lower
detection limit of the assay could be demonstrated in all
of them. Interestingly, a group of four patients with IL6
levels ≥ 20 pg/ml had a different clinical course than the
other eight patients with lower levels (Table 1). Two of
the four patients with higher IL6 levels had fever at diag-
nosis, and three of these four patients metastases at first
diagnosis; all four patients died of their disease. In con-
trast, only two of the eight patients with IL6 levels below
20 pg/ml had fever, metastases and died of their disease.
ES tumors and cell lines express the IL6 receptor
complex, IL6R and IL6ST
The IL6 receptor complex is composed of two subunits:
IL6R, the IL6 interacting part, and IL6ST, which interacts
with the IL6R/IL6 complex. IL6ST mediates intracellular
signal transduction. Applying RT-PCR to 7 tumor speci-
mens we were able to show pronounced expression of
both subunits in most tumor biopsies (Fig. 1a).
Analysis of the expression of both subunits in cell lines
gave similar results (Fig. 1b). All ES cell lines showed
constitutively high level IL6ST- and variable IL6R ex-
pression. Maximal IL6R abundance was found in the cell
line A4573, lowest levels in SK-N-MC cells.
Flow cytometric analysis was applied to investigate
whether IL6R and IL6ST were expressed on the cell sur-
face of ES cells. High surface expression of IL6ST was
noted for all cell lines. In line with the mRNA expression
pattern, IL6R protein occurred at lower and variable
levels, and was not detectable in cell line JR. The prostate
cancer cell line LNCaP, used as an IL6R positive control,
had similar expression levels of IL6R and IL6ST compared
to ES cell lines (Fig. 1c and Additional file 1: Figure S1).
The IL6 receptor complex is functional in ES cell lines
Interaction of IL6 with IL6R and subsequent formation
of the heterodimer with IL6ST leads to phosphorylation
of STAT3. To analyze the functionality of the IL6 re-
ceptor complex in ES cells, we performed STAT3
phospho-immunoblots of 8 ES cell lines (Fig. 2a and
data not shown). In three cell lines – A4573, TC32 and
CHP-100 – incubation with rhIL6 led to Tyr705-
phosphorylation of STAT3 at IL6 concentrations as low
as 50 ng/ml. All cell lines revealed low intrinsic activa-
tion of STAT3. Treatment of cell lines 5838, SB and JR
with rhIL6 did not have any effect on STAT3 phosphor-
ylation (Fig. 2a and data not shown). Regarding the
Table 1 Serum IL6 levels at initial diagnosis of ES in 12 patients
measured by ELISA
IL6 ≥ 20 pg/ml IL6 < 20 pg/ml
Patients 4 8
Fever at diagnosis 2 2
Metastasis at diagnosis 3 2
Death, due to disease progression 4 3
IL6-positive tumor (RT-PCR or IHC) 2/3 1/5
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time course of STAT3 phosphorylation after incubation
with rhIL6, A4573 cells showed increased phosphoryl-
ation of STAT3 as early as 5 min after treatment with
rhIL6, and maximal levels after 20 – 40 min. After
2 h STAT3 activation was reduced but still detectable
(Fig. 2b).
Phosphorylation of STAT3 could be attributed to a
functional IL6 receptor complex, since interference of
the IL6R/IL6 interaction by an anti-IL6R-antibody, ap-
plied 30 min prior to treatment of the cells with rhIL6,
completely inhibited STAT3 phosphorylation in both
LNCaP positive control and A4573 ES cells. Consistent
with the lack of protein expression of IL6R on the cell
surface (Fig. 2c and data not shown), no STAT3
phosphorylation was detected in cell line JR after incu-
bation with rhIL6.
IL6 rescues ES cells from apoptosis during serum
starvation
Since IL6 is known to stimulate proliferation and to in-
hibit apoptosis in various tumors, we first examined the
influence of rhIL6 on cell growth in the ES cell line
A4573. The functional IL6 receptor complex in A4573
cells triggers phosphorylation of STAT3 once cells are
subjected to IL6. Judged by the number of viable cells 24
and 48 h post stimulation by MTT assay, however, a sin-
gle bolus of rhIL6 was ineffective to induce proliferation
of cells kept in serum-free medium (data not shown). As
Fig. 1 a IL6R and IL6ST mRNA expression of seven ES tumor samples by RT-PCR. IFN-γ treated PBMC were used as positive control (left lane). All
tumor specimens expressed both IL6 receptor subunits. b IL6R and IL6ST mRNA expression in nine ES cell lines (RT-PCR). IFN-γ treated PBMC were
used as positive controls (left lane). c Assessment of IL6 receptor complex cell surface expression by flow cytometry. The prostate cancer cell line
LNCaP was used as a positive control. IL6R and IL6ST cell surface staining of 4 additional ES cell lines is shown in Additional file 1: Figure S1
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a consequence we decided to stimulate cell prolifera-
tion through repeated rhIL6 applications to aim for IL6
concentrations that remain more or less elevated over
an extended time period mimicking more physiologic
conditions.
Cells of all subgroups (untreated controls, single-bolus
IL6 and repetitively treated with IL6) continued to grow
until day 3, followed by a decline in viable cells on day 4
and further on day 5. Stimulating serum-starved A4573
cells through repetitive applications of rhIL6 (d0, d2, d4
at 10 ng/ml) yielded, compared to untreated (control) or
single-bolus treated (d0) cells, a slight increase in the
number of viable cells on day 3 and a significantly
smaller decline in the fraction of viable cells on days
four and five post-stimulation as indicated in Fig. 3a. To
further characterize the cause for the improved viability
of serum-deprived yet serially IL6 exposed cells, we ana-
lyzed the sub-G1 content of cells by flow cytometry. Ac-
cording to these data, serial treatment of ES cells with
rhIL6 inhibited apoptosis, in turn yielding a higher num-
ber of viable A4573 cells (Fig. 3b).
IL6 promotes migration of ES cells
Since IL6 promotes cell dissemination in a great variety
of tumors we thus analyzed migration of A4573/GFP ES
tumor cells in CAM assays. As depicted in Fig. 4, single
high-dose rhIL6 application was sufficient in triggering a
higher degree of cell migration into regions distal from
the primary tumor (zone 1) compared to PBS-treated
controls. We found a significant increase in cell dissem-
ination using 250 ng/ml and 500 ng/ml rhIL6, relative to
a PBS load of equal volume. Moreover, 500 ng/ml rhIL6
increased migration into zone 1 to a larger extent than
the lower rhIL6 dose.
IL6 is expressed by cells of the tumor microenvironment
To gain deeper insight into the origin of IL6 production
in ES patients, we analyzed the expression of IL6 mRNA
and protein in ES cell lines and their supernatants as
well as in biopsy specimens of primary tumors.
Analysis of IL6 mRNA expression in 9 ES cell lines by
RT-PCR showed detectable transcript levels in four of
them, with cell lines A4573 and JR displaying the highest
expression levels. CHP-100 and SK-N-MC lines demon-
strated much lower levels (Fig. 5b). Except for CHP-100,
IL6 mRNA positive cell lines secreted detectable con-
centrations of IL6 protein (ELISA detection) into the
supernatant when incubated for 48 h in serum without
supplements. Levels of secreted IL6 in the supernatant
were low, except for cell line JR (Table 2).
Similar to ES cell lines, of which 4 out of 9 expressed
mRNA for IL6, only three of seven tumor biopsies
Fig. 2 a p-STAT3 phospho-specific immunoblot of four ES cell lines. rhIL6-mediated STAT3 activation was detected after 20 min incubation of
indicated IL6 concentrations in cell lines A4573, TC32 and CHP. All cell lines showed low intrinsic phosphorylation of STAT3. Cell line 5838 did
not display an increase in p-STAT3 after incubation with rhIL6. b p-STAT3 phospho-specific immunoblot of cell line A4573 after incubation
with 50 ng/ml rhIL6 for indicated time periods. Maximal levels of phosphorylated STAT3 were seen 20 min after adding rhIL6. STAT3
phosphorylation decreased after 2 h of incubation. c Phosphorylation of STAT3 in A4573 ES cell line is IL6-specific. Cells were stimulated with
rhIL6 (100 ng/ml for 20 min). An IL6 receptor-specific antagonistic antibody (2 μg/ml) was added 30 min prior to rhIL6 incubation where
indicated. The prostate cancer cell line LNCaP was used as a positive control. STAT3 phosphorylation mediated by rhIL6 could be blocked by
an anti-IL6 receptor antibody. Data representative for three independent protein harvests and immunoblots
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Fig. 4 a Immunofluorescence of A4573/GFP ES cells grown on a CAM and treated with single IL6 dose as indicated. b Cell coverage across
equal-size zones 3, 2 and 1 (right) was estimated by superimposed 3 × 12 square area with values ranging from 0 (no cells present) to 5 (square
100 % filled with cells). See Methods for details. The bar graph (left) illustrates relative mean (± SEM) coverage values for zones 3, 2 and 1 from a
total of three independent experiments as a measure of cell motility in response to same-volume applications of PBS, 250 ng and 500 ng rhIL6.
Addition of rhIL6 dose-dependently and significantly (* = p < 0.05) increased motility of A4573 ES cells on the surface of the CAM from zone 3
(explant perimeter) to zone 1 (furthest distance)
Fig. 3 a Increased viability of serum-starved A4573 ES cells by repetitive stimulation with rhIL6 (d 0, 2, 4; 10 ng/ml). Fold-change (x) of
MTT conversion rates (n = 5; mean ± SD) relative to rates of cells measured 24 h after seeding and set to 1 (100 %) are shown. Statistical
significance of IL6 treatment relative to controls is indicated (Mann–Whitney-U-Test; * = p < 0.05). b Serial supply of rhIL6 reduces rate of
apoptosis from serum starvation in A4573 ES cells. Serum-starved cells of ES cell line A4573 cells were stimulated repetitively with rhIL6
(10 ng/ml on indicated days) and harvested on day 5. Sub-G1 DNA content was used as a measure of apoptosis. Bars (n = 3; mean ± SD)
indicate fraction of cells (%) containing a sub-G1 DNA content. Similar results could be shown in two other independent experiments
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expressed mRNA for IL6 (Fig. 5a). This is in contrast to
the expression of the IL6 receptor subunits, which were
found in all cell lines and tumor samples. Consequently,
the origin of IL6 in serum of patients with Ewing sar-
coma might not be attributed to the ES cells themselves
in all instances.
To further examine possible sources of IL6 in ES we
used an αIL6 antibody to stain tumor specimens from 4
ES patients. As demonstrated in Fig. 6 and Additional
file 2: Figure S2, IL6 expression was found mainly in the
intraseptal regions of tumor sections. By further immu-
nohistochemical staining against vimentin and smooth
muscle antigen (SMA), the cells in the septa were identi-
fied as fibroblasts by positivity for both markers. Within
the septa no other significant cell population could be iden-
tified, except of very rare single lymphocytes and histio-
cytes. ES cells themselves were found to be IL6- negative.
Comparing IL6 serum level with IL6 expression in ES
tumor tissue by RT-PCR or immunohistochemistry in 8 pa-
tients, we found that two of three patients with IL6-positive
tumors had IL6 serum level ≥ 20 pg/ml at diagnosis,
whereas four of five patients with IL6-negative tumors had
serum IL6 levels < 20 pg/ml (Table 1, Additional file 2:
Figure S2). Consequently, the tumor microenvironment
could be a source of IL6 detected in the serum of ES pa-
tients and paracrine mechanisms are possible to govern
apoptotic or disseminating cell fates.
Discussion
Our results demonstrate that the IL6 pathway is func-
tional in ES cells. Treatment of ES cells in vitro and
CAM grafts with rhIL6 inhibited apoptosis and sup-
ported cell dissemination. Evidence of IL6 expression in
the tumor stroma of primary ES and dismal prognosis of
patients presenting with higher IL6 levels at diagnosis
further suggest a biological relevance of this cytokine in
ES pathogenesis.
IL6 has a wide range of tumor promoting activities in
a large variety of cancer cells. Its impact on malignant
cells includes the stimulation of anti-apoptotic, prolifera-
tive and migratory activities, thereby enhancing tumor
initiation and progression (reviewed in [6, 7]). Two years
ago Blanchard et al. published the first investigation of
the biological effects of different cytokines including IL6
in bone sarcoma cells. In their work, treatment with
rhIL6 and sIL6R for 3 days in serum-depleted media
(1 % FBS) enhanced proliferation in 10 different ES cell
lines [35]. Though we did not observe enhancement of
cell proliferation by IL6 in our serum-free system, IL6
protected cells from apoptosis through serum starvation.
Fig. 5 a Detection of IL6 mRNA expression in 7 ES tumor samples using RT-PCR. IFN-γ treated PBMC were used as positive control. 3 out of 7
tumor samples expressed IL6 mRNA. b IL6 mRNA expression in 9 ES cell lines by RT-PCR. IFN-γ treated PBMC were used as positive control. 4 out
of 9 cell lines expressed IL6 mRNA
Table 2 Concentration of IL6 in the supernatant of 5 ES cell
lines cultured in vitro (ELISA)
ES cell line IL6 concentration (pg/ml)
A4573 14.43 ± 0.15
TC71 <2
SK-N-MC 2.50 ± 0.44
CHP-100 <2
JR 279.67 ± 24.70
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Observations of IL6 action under circumstances of cell
stress in other tumor cell models support our results. In
neuroblastoma, IL6 enhanced cell survival in cells culti-
vated in serum-deprived media [14, 36]. This protective
effect was shown to be linked to the induction of F-
thrombospondin [36].
Micrometastasis and systemic disease are one of the
key features of ES [3]. Applying CAM assay we demon-
strated a significant increase in ES cell dissemination
into the CAM in response to single bolus treatment with
a relatively high-dose of rhIL6. In contrast, non-treated
cells, showing low-level intrinsic expression of IL6, had
only scattered cells at more distant tumor sites. Our re-
sults are in concordance with data for breast cancer and
glioblastoma showing IL6-dependent promotion of cell
invasion into the basal membrane and CAM, respect-
ively [37, 38].
Analyzing the IL6 signaling pathway we detected ex-
pression of receptor molecules IL6R and IL6ST by RT-
PCR and flow cytometry in virtually all cell lines studied.
This is similar to data for neuroblastoma showing ex-
pression of IL6R/IL6R mRNA in most of the cell lines
studied [14]. RT-PCR analysis of primary ES tumors
confirmed the expression pattern of cell lines with strong
expression of IL6R and IL6ST in all tumor samples. Appli-
cation of rhIL6 to ES cells led via the IL6R/IL6ST complex
to STAT3 activation which is known to induce the expres-
sion of genes protecting from apoptosis and promoting
migration.
In contrast to the expression of the IL6 receptor com-
ponents in almost all ES cell lines and tumor samples,
IL6 was found to be expressed in less than half of tu-
mors applying RT-PCR. To explore the cellular origin of
IL6 detected in the serum of ES patients, we performed
immunohistochemistry on ES tumors. We found that a
subgroup of ES tumors strongly expressed IL6 in the
tumor connective tissue septa. Interestingly, these pa-
tients also had high IL6 serum levels indicating that IL6
secreted by ES tumor adjacent fibroblasts could be a
major source for IL6 detected in the serum of ES pa-
tients. A similar immunohistochemical IL6 expression
pattern has been described in primary colon carcinoma
and invasive mammary carcinoma [39, 40]. Among other
cell types, cancer-associated fibroblasts (CAF) stained
positive for IL6 [6]. In addition, Rakan et al. demon-






Fig. 6 Immunohistochemical analysis of two ES tumor specimens and control tissues for IL6, vimentin and smooth muscle actin (SMA). Pictures A
and B show staining of control tissues with anti-IL6-ab (both 200×): a Appendix: positive staining of cells/extracellular space of lamina propria. b Tonsil:
positive staining of cells/extracellular space in center of lymphoid follicles. Pictures C and D: examples of ES, negative and positive for IL6. c1 and c2
negative for IL6 in connective tissue septa within the tumor (Pt. 8). d1 and d2) positive for IL6 in connective tissue septa within the tumor (Pt. 7). In both
samples no staining could be observed in tumor tissue. c1 and d1: 100×, c2 and d2: 200×. Pictures e1-e3: comparison of different stainings of ES,
positive case (Pt. 7), all 200×): e1 IL6 staining, showing positivity in connective tissue septa between negative (blue) tumor cells. e2 Staining against
vimentin demonstrates mesenchymal character of both tumor cells and cells in connective tissue septa. e3 Smooth muscle actin highlights the cells
within the connective tissue septa, defining them as fibroblasts
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and invasiveness of breast cancer cells, emphasizing the
role of the microenvironment [41].
Key biological features underlying the development of
solid malignancies – uncontrolled cell division and
growth, angiogenesis, invasion and metastasis – are all
linked to inflammation [5]. Since it has been shown be-
fore that ES patients presenting with fever at diagnosis
had a higher risk for metastases and death from their
disease [9], and that IL6 is a main mediator of the febrile
systemic response [42], we were intrigued to correlate
IL6 serum levels with clinical data from ES patients. We
found that 2 out of 4 patients with IL6 levels ≥ 20 pg/ml
had fever and 3 out of 4 metastases at diagnosis,
whereas only two out eight patients with IL6 levels
below 20 pg/ml presented with fever and metastases at
diagnosis. Though this patient cohort is too small for
any statistical analysis, it indicates that IL6 might at
least partly play a role in mediating effects such as
fever and formation of metastases. This hypothesis is
supported by results of a study by Rutkowski et al.
who found elevated serum levels of IL6 to strongly
correlate with tumor size, and inversely with OS and
DFS in patients with malignant bone tumors, includ-
ing patients with ES [10].
Due to the small group size, a prognostic impact of
IL6 serum levels in ES patients at initial diagnosis on
survival cannot be inferred from our data. Nevertheless,
our data point to the need for a systematic analysis in a
greater patient cohort aiming to elucidate the prognostic
value of IL6 serum levels in ES patients.
Conclusion
We were able to show a substantial contribution of
rhIL6 in the inhibition of ES cell death during a period
of cell stress. In particular, cells located in central,
vessel-remote areas of the tumor are known to suffer
from critical shortages of supplied nutrients and oxygen.
IL6 might support mechanisms to overcome the hyp-
oxic/ischemic challenge until vascularization and nutri-
tional status improve. Furthermore, IL6 promotes cell
dissemination to support evasion from poorly supplied
tumor areas. Future studies should provide insights into
the gene expression changes that are triggered in ES
cells subjected to persistent rhIL6 exposure and required
in yielding the anti-apoptotic and pro-disseminating ES
responses.
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